Navidea Biopharmaceuticals (NAVB) 10-Q 9 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 02, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Trading Symbol	NAVB
Entity Central Index Key	810,509
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		155,699,665

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 11,370,420	$ 5,479,006
Accounts receivable, net	1,909,372	816,544
Inventory, net	877,183	932,385
Prepaid expenses and other	807,687	1,371,210
Total current assets	14,964,662	8,599,145
Property and equipment	3,862,440	4,124,028
Less accumulated depreciation and amortization	1,805,113	1,614,320
Property and equipment, net	2,057,327	2,509,708
Patents and trademarks	233,596	219,558
Less accumulated amortization	45,701	38,725
Patents and trademarks, net	187,895	180,833
Investment in R-NAV, LLC		241,575
Other assets	273,573	299,047
Total assets	17,483,457	11,830,308
Current liabilities:
Accounts payable	1,298,879	1,477,499
Accrued liabilities and other	3,602,891	3,234,120
Deferred revenue, current	1,002,531
Notes payable, current, net of discounts of $0 and $863,813, respectively	333,333	4,348,678
Total current liabilities	6,237,634	9,060,297
Deferred revenue	416,667
Notes payable, net of discounts of $2,102,947 and $1,585,882, respectively	60,946,844	29,484,057
Other liabilities	1,701,939	3,089,420
Total liabilities	$ 69,303,084	$ 41,633,774
Commitments and contingencies
Stockholders’ deficit:
Preferred stock; $.001 par value; 5,000,000 shares authorized; 0 and 4,519 Series B shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively		$ 4
Common stock; $.001 par value; 200,000,000 shares authorized; 150,703,485 and 150,200,259 shares issued and outstanding at September 30, 2015 and December 31, 2014,respectively	$ 150,703	150,200
Additional paid-in capital	325,596,476	323,030,301
Accumulated deficit	(378,036,538)	(352,983,971)
Total Navidea stockholders' deficit	(52,289,359)	(29,803,466)
Noncontrolling interest	469,732
Total stockholders’ deficit	(51,819,627)	(29,803,466)
Total liabilities and stockholders’ deficit	$ 17,483,457	$ 11,830,308

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Common Stock, Par or Stated Value Per Share (USD per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	150,703,485	150,200,259
Common Stock, Shares Outstanding	150,703,485	150,200,259
Series B Preferred Stock
Preferred Stock, Par or Stated Value Per Share (USD per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	4,519
Preferred Stock, Shares Outstanding	0	4,519
Notes Payable Current
Notes payable, discounts	$ 0	$ 863,813
Notes Payable Non Current
Notes payable, discounts	$ 2,102,947	$ 1,585,882

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
Lymphoseek sales revenue	$ 2,952,522	$ 1,101,071	$ 6,751,492	$ 2,773,959
Lymphoseek license revenue	550,000	300,000	883,333	300,000
Grant and other revenue	476,755	848,999	1,320,816	1,002,605
Total revenue	3,979,277	2,250,070	8,955,641	4,076,564
Cost of goods sold	457,590	807,880	1,239,377	1,271,598
Gross profit	3,521,687	1,442,190	7,716,264	2,804,966
Operating expenses:
Research and development	3,902,155	4,158,085	10,180,517	14,496,977
Selling, general and administrative	3,942,609	2,646,591	13,485,576	11,465,076
Total operating expenses	7,844,764	6,804,676	23,666,093	25,962,053
Loss from operations	(4,323,077)	(5,362,486)	(15,949,829)	(23,157,087)
Other income (expense):
Interest expense, net	(2,148,369)	(918,026)	(4,690,686)	(2,764,122)
Equity in loss of R-NAV, LLC	(26,785)	(262,198)	(295,217)	(262,198)
Change in fair value of financial instruments	(1,577,275)	(409,650)	(1,702,902)	(109,499)
Loss on extinguishment of debt			(2,440,714)	(2,610,196)
Other, net	4,402	53,464	26,100	41,419
Total other income (expense), net	(3,748,027)	(1,536,410)	(9,103,419)	(5,704,596)
Net loss	(8,071,104)	(6,898,896)	(25,053,248)	(28,861,683)
Less loss attributable to noncontrolling interest	(340)		(681)
Deemed dividend on beneficial conversion feature of MT Preferred Stock			(46,000)
Net loss attributable to common stockholders	$ (8,070,764)	$ (6,898,896)	$ (25,098,567)	$ (28,861,683)
Loss per common share (basic and diluted)	$ (0.05)	$ (0.05)	$ (0.17)	$ (0.19)
Weighted average shares outstanding (basic and diluted)	150,186,131	150,169,712	150,030,638	148,344,064

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - 9 months ended Sep. 30, 2015 - USD ($)	Total	Preferred Stock	Preferred StockSeries B Preferred Stock	Common Stock	Additional Paid-In Capital	Additional Paid-In CapitalSeries B Preferred Stock	Accumulated Deficit	Non-controlling Interest
Balance at Dec. 31, 2014	$ (29,803,466)	$ 4		$ 150,200	$ 323,030,301		$ (352,983,971)
Balance, shares at Dec. 31, 2014		4,519		150,200,259
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issued stock upon exercise of stock options, net	54,330			$ 124	54,206
Issued stock upon exercise of stock options, net, shares				124,238
Issued restricted stock	354			$ 354
Issued restricted stock, shares				354,000
Canceled forfeited restricted stock				$ (108)	108
Canceled forfeited restricted stock, shares				(108,000)
Canceled stock to pay employee tax obligations	(12,614)			$ (7)	(12,607)
Canceled stock to pay employee tax obligations, shares				(7,645)
Issued stock in payment of Board retainers	131,261			$ 72	131,189
Issued stock in payment of Board retainers, shares				72,476
Issued stock to 401(k) plan	117,099			$ 68	117,031
Issued stock to 401(k) plan, shares				68,157
Exchanged Series B Preferred Stock for warrants			$ (4)			$ 4
Exchanged Series B Preferred Stock for warrants, shares			(4,519)
Extension of warrant expiration date	149,615				149,615
Issued warrants in connection with advisory services agreement	256,450				256,450
Stock compensation expense	1,916,179				1,916,179
Net loss	(25,053,248)						(25,052,567)	$ (681)
Issuance of MT Preferred Stock, net of deemed dividend on beneficial conversion feature	424,413				(46,000)			470,413
Balance at Sep. 30, 2015	$ (51,819,627)			$ 150,703	$ 325,596,476		$ (378,036,538)	$ 469,732
Balance, shares at Sep. 30, 2015				150,703,485

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (25,053,248)	$ (28,861,683)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	431,368	360,702
Loss on disposal and abandonment of assets	33,184	31,794
Change in reserve for uncollectible accounts	16,000
Change in inventory reserve and other adjustments to inventory	138,914	539,027
Amortization of debt discount and issuance costs	423,522	637,565
Compounded interest on long term debt	1,231,125
Stock compensation expense	1,916,179	1,032,244
Equity in loss of R-NAV, LLC	295,217	262,198
Change in fair value of financial instruments	1,702,902	109,499
Loss on extinguishment of debt	2,440,714	2,610,196
Issued stock to 401(k) plan for employer matching contributions	117,099	100,044
Extension of warrant expiration date	149,615
Issued warrants in connection with advisory services agreement	256,450
Other	77,620
Changes in operating assets and liabilities:
Accounts receivable	(1,108,828)	(314,800)
Inventory	(83,712)	573,191
Prepaid expenses and other assets	588,996	(109,116)
Accounts payable	(178,620)	(45,410)
Accrued and other liabilities	305,170	(1,226,288)
Deferred revenue	1,419,198
Net cash used in operating activities	(14,881,135)	(24,300,837)
Cash flows from investing activities:
Purchases of equipment	(30,406)	(1,111,418)
Proceeds from sales of equipment	38,265
Patent and trademark costs	(27,092)	(51,876)
Investment in R-NAV, LLC		(333,334)
Net cash used in investing activities	(19,233)	(1,496,628)
Cash flows from financing activities:
Proceeds from issuance of MT Preferred Stock and warrants	500,000
Payment of issuance costs related to MT Preferred Stock and warrants	(12,587)
Proceeds from issuance of common stock and short swing profits	65,975	87,982
Payment of tax withholdings related to stock-based compensation	(23,906)	(75,759)
Proceeds from notes payable	54,500,000	30,000,000
Payment of debt-related costs	(3,902,487)	(1,763,526)
Principal payments on notes payable	(30,333,333)	(25,000,000)
Payments under capital leases	(1,880)	(1,640)
Net cash provided by financing activities	20,791,782	3,247,057
Net increase (decrease) in cash	5,891,414	(22,550,408)
Cash, beginning of period	5,479,006	32,939,026
Cash, end of period	$ 11,370,420	$ 10,388,618

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies a. Basis of Presentation : The information presented as of September 30, 2015 and for the three-month and nine-month periods ended September 30, 2015 and 2014 is unaudited, but includes all adjustments (which consist only of normal recurring adjustments) that the management of Navidea Biopharmaceuticals, Inc. (Navidea, the Company, or we) believes to be necessary for the fair presentation of results for the periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The balances as of September 30, 2015 and the results for the interim periods are not necessarily indicative of results to be expected for the year. The consolidated financial statements should be read in conjunction with Navidea’s audited consolidated financial statements for the year ended December 31, 2014, which were included as part of our Annual Report on Form 10-K. Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Limited and Cardiosonix Ltd, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (MT). All significant inter-company accounts were eliminated in consolidation. Navidea's investment in R-NAV, LLC (R-NAV) is being accounted for using the equity method of accounting and is therefore not consolidated. b. Financial Instruments and Fair Value: In accordance with current accounting standards, the fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value, giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2 – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In determining the appropriate levels, we perform a detailed analysis of the assets and liabilities whose fair value is measured on a recurring basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 2. The following methods and assumptions were used to estimate the fair value of each class of financial instruments: (1) Cash, accounts receivable, accounts payable, and accrued liabilities: The carrying amounts approximate fair value because of the short maturity of these instruments. (2) Notes payable: The carrying value of our debt at September 30, 2015 and December 31, 2014 primarily consists of the face amount of the notes less unamortized discounts. See Note 8. At September 30, 2015 and December 31, 2014, certain notes payable were also required to be recorded at fair value. The estimated fair value of our debt was calculated using a discounted cash flow analysis as well as a Monte Carlo simulation. These valuation methods include Level 3 inputs such as the estimated current market interest rate for similar instruments with similar creditworthiness. For the debt recorded at fair value, unrealized gains and losses on the fair value of the debt are classified in other expenses as a change in the fair value of financial instruments in the consolidated statements of operations. At September 30, 2015, the fair value of our notes payable is approximately $64.2 million, compared to the carrying value of $61.3 million. (3) Derivative liabilities: Derivative liabilities are related to certain outstanding warrants which are recorded at fair value. Derivative liabilities totaling $63,000 as of September 30, 2015 were included in other liabilities on the consolidated balance sheets. No derivative liabilities were outstanding as of December 31, 2014. The assumptions used to calculate fair value as of September 30, 2015 included volatility, a risk-free rate and expected dividends. In addition, we considered non-performance risk and determined that such risk is minimal. Unrealized gains and losses on the derivatives are classified in other expenses as a change in the fair value of financial instruments in the statements of operations. See Notes 2 and 6. c. Revenue Recognition: We currently generate revenue primarily from sales of Lymphoseek ® We earn additional revenues based on a percentage of the actual net revenues achieved by Cardinal Health on sales to end customers made during each fiscal year. The amount we charge Cardinal Health related to end customer sales of Lymphoseek are subject to a retroactive annual adjustment. To the extent that we can reasonably estimate the end-customer prices received by Cardinal Health, we record sales based upon these estimates at the time of sale. If we are unable to reasonably estimate end customer sales prices related to products sold, we record revenue related to these product sales at the minimum (i.e., floor) price provided for under our distribution agreement with Cardinal Health. We also earn revenues related to our licensing and distribution agreements. The terms of these agreements may include payment to us of non-refundable upfront license fees, funding or reimbursement of research and development efforts, milestone payments if specified objectives are achieved, and/or royalties on product sales. We evaluate all deliverables within an arrangement to determine whether or not they provide value on a stand-alone basis. We recognize a contingent milestone payment as revenue in its entirety upon our achievement of a substantive milestone if the consideration earned from the achievement of the milestone (i) is consistent with performance required to achieve the milestone or the increase in value to the delivered item, (ii) relates solely to past performance and (iii) is reasonable relative to all of the other deliverables and payments within the arrangement. We received a non-refundable upfront cash payment of $2.0 million from SpePharm AG upon execution of the SpePharm License Agreement in March 2015. We have determined that the license and other non-contingent deliverables do not have stand-alone value because the license could not be deemed to be fully delivered for its intended purpose unless we perform our other obligations, including specified development work. Accordingly, they do not meet the separation criteria, resulting in these deliverables being considered a single unit of account. As a result, revenue relating to the upfront cash payment was deferred and is being recognized on a straight-line basis over the estimated obligation period of two years. We generate additional revenue from grants to support various product development initiatives. We generally recognize grant revenue when expenses reimbursable under the grants have been paid and payments under the grants become contractually due. Lastly, we recognize revenues from the provision of services to R-NAV and its subsidiaries. See Note 7. d. Change in Accounting Principle: In April 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-03, Simplifying the Presentation of Debt Issuance Costs . ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability rather than as an asset. The recognition and measurement guidance for debt issuance costs are not affected by ASU 2015-03. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted. Entities must apply the amendments in ASU 2015-03 on a retrospective basis. During the second quarter of 2015, the Company elected early adoption of ASU 2015-03. The consolidated balance sheet as of December 31, 2014 has been adjusted to reflect retrospective application of the new method of presentation. Deferred debt issuance costs totaling $90,000 that were included in other assets as of December 31, 2014 were reclassified as discounts on notes payable, current, of $35,000 and discounts on notes payable, long term, of $55,000. We have reflected these unamortized costs as a reduction of the debt on the balance sheet as of September 30, 2015 and will continue to do so in future periods. The adoption of ASU 2015-03 had no impact on the consolidated statements of operations, stockholders' deficit or cash flows. e. Recent Accounting Pronouncements: In February 2015, the FASB issued ASU No. 2015-02, Amendments to the Consolidation Analysis . ASU 2015-02 affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. All legal entities are subject to reevaluation under the revised consolidation model. Specifically, the amendments: (i) modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities, (ii) eliminate the presumption that a general partner should consolidate a limited partnership, and (iii) affect the consolidation analysis of reporting entities that are involved with VIEs, particularly those that have fee arrangements and related party relationships. ASU 2015-02 is effective for public entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The amendments may be applied using a modified retrospective approach or a full retrospective approach. Early adoption is permitted, including adoption in an interim period. We are currently evaluating the impact of our adoption of ASU 2015-02, however we do not expect the adoption of ASU 2015-02 to have a material effect on our consolidated financial statements upon adoption. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers

Fair Value

Fair Value	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value	2. Fair Value As discussed in Note 8, under the First and Second Amended Platinum Notes, Platinum-Montaur Life Sciences, LLC (Platinum) had the right to convert all or any portion of the unpaid principal or unpaid interest accrued on any draws subsequent to the second quarter of 2013 under the Platinum credit facility into Navidea common stock, under certain circumstances. In May 2015, Navidea and Platinum executed a Third Amended Platinum Note, which extends Platinum's right to convert any portion of the unpaid principal or unpaid interest to all draws under the credit facility, including those made prior to the second quarter of 2013. The Third Amended Platinum Note also changed other provisions of the Platinum Loan Agreement as discussed further in Note 8. Platinum’s debt instrument, including the embedded option to convert such debt into common stock, is recorded at fair value on the consolidated balance sheets. The estimated fair value of the Platinum notes payable is $12.3 million at September 30, 2015. MT issued warrants to purchase 300 shares of MT Common Stock in connection with the sale of 10 shares of MT Preferred Stock in March 2015. The warrants have certain characteristics including a net settlement provision that require the warrants to be accounted for as a derivative liability at fair value, with subsequent changes in fair value included in earnings. The estimated fair value of the MT warrants is $63,000 at September 30, 2015, and will continue to be measured on a recurring basis. See Notes 1(b)(3) and 6. The following tables set forth, by level, financial liabilities measured at fair value on a recurring basis: Liabilities Measured at Fair Value on a Recurring Basis as of September 30, 2015 Description Quoted Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Platinum notes payable $ — $ — $ 12,280,513 $ 12,280,513 Liability related to warrants — — 63,000 63,000 Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2014 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Platinum notes payable $ — $ — $ 5,615,764 $ 5,615,764 a. Valuation Processes-Level 3 Measurements: Depending on the instrument, the Company utilizes discounted cash flows, option pricing models, or third-party valuation services to estimate the value of their financial assets and liabilities. Valuations using discounted cash flow methods and certain option pricing models such as Black-Scholes are generally conducted by the Company or by third-party valuation experts. Valuations using complex models such as a Monte Carlo simulation are generally provided to the Company by third-party valuation experts. Each reporting period, the Company provides significant unobservable inputs to the third-party valuation experts based on current internal estimates and forecasts. b. Sensitivity Analysis-Level 3 Measurements: Changes in the Company’s current internal estimates and forecasts are likely to cause material changes in the fair value of certain liabilities. The significant unobservable inputs used in the fair value measurement of the liabilities include the amount and timing of future draws expected to be taken under the Platinum Loan Agreement based on current internal forecasts. Significant increases (decreases) in any of the significant unobservable inputs would result in a higher (lower) fair value measurement. A change in one of the inputs would not necessarily result in a directionally similar change in the others. There were no Level 1 liabilities outstanding at any time during the three-month and nine-month periods ended September 30, 2015 and 2014. There were no transfers in or out of our Level 2 liabilities during the three-month and nine-month periods ended September 30, 2015 or 2014. Changes in the estimated fair value of our Level 3 liabilities relating to unrealized gains (losses) are recorded as changes in fair value of financial instruments in the consolidated statements of operations. The change in the estimated fair value of our Level 3 liabilities during the three-month periods ended September 30, 2015 and 2014 was $1.6 million and $410,000, respectively. The change in the estimated fair value of our Level 3 liabilities during the nine-month periods ended September 30, 2015 and 2014 was $1.7 million and $109,000, respectively.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	3. Stock-Based Compensation At September 30, 2015, we have instruments outstanding under two stock-based compensation plans; the Amended and Restated 2002 Stock Incentive Plan (the 2002 Plan) and the Amended and Restated 2014 Stock Incentive Plan (the 2014 Plan). Total shares authorized under each plan are 12 million shares and 5 million shares, respectively. In addition, we have stock options outstanding that were awarded as an employment inducement in connection with the appointment of our new CEO in October 2014. Currently, under the 2014 Plan, we may grant incentive stock options, nonqualified stock options, and restricted stock awards to full-time employees and directors, and nonqualified stock options and restricted stock awards may be granted to our consultants and agents. Although instruments are still outstanding under the 2002 Plan, the plan has expired and no new grants may be made from it. Under both plans, the exercise price of each option is greater than or equal to the closing market price of our common stock on the date of the grant. Stock options granted under the 2002 Plan and the 2014 Plan generally vest on an annual basis over one to four years. The stock options that were awarded as an employment inducement in connection with the appointment of our CEO will vest in three tranches based on certain service and market conditions as defined in the agreement. Outstanding stock options under the plans, if not exercised, generally expire ten years from their date of grant or up to 90 days following the date of an optionee’s separation from employment with the Company. We issue new shares of our common stock upon exercise of stock options. Stock-based payments to employees and directors, including grants of stock options, are recognized in the consolidated statements of operations based on their estimated fair values. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. Expected volatilities are based on the Company’s historical volatility, which management believes represents the most accurate basis for estimating expected future volatility under the current circumstances. Navidea uses historical data to estimate forfeiture rates. The expected term of stock options granted is based on the vesting period and the contractual life of the options. The risk-free rate is based on the U.S. Treasury yield in effect at the time of the grant. The portion of the fair value of stock-based awards that is ultimately expected to vest is recognized as compensation expense over either (1) the requisite service period or (2) the estimated performance period. Restricted stock awards are valued based on the closing stock price on the date of grant and amortized ratably over the estimated life of the award. Restricted stock may vest based on the passage of time, or upon occurrence of a specific event or achievement of goals as defined in the grant agreements. In such cases, we record compensation expense related to grants of restricted stock based on management’s estimates of the probable dates of the vesting events. Stock-based awards that do not vest because the requisite service period is not met prior to termination result in reversal of previously recognized compensation cost. For the three-month periods ended September 30, 2015 and 2014, our total stock-based compensation expense, which includes reversals of expense for certain forfeited or cancelled awards, was approximately $397,000 and $(528,000), respectively. For the nine-month periods ended September 30, 2015 and 2014, our total stock-based compensation expense was approximately $1.9 million and $1.0 million, respectively. We have not recorded any income tax benefit related to stock-based compensation in either of the three-month and nine-month periods ended September 30, 2015 and 2014. A summary of the status of our stock options as of September 30, 2015, and changes during the nine-month period then ended, is presented below: Nine Months Ended September 30, 2015 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at beginning of period 5,345,764 $ 2.16 Granted 1,365,400 1.67 Exercised (146,625 ) 0.61 Canceled and Forfeited (1,081,725 ) 2.82 Expired (5,750 ) 1.26 Outstanding at end of period 5,477,064 $ 1.95 7.4 years $ 3,058,790 Exercisable at end of period 2,222,049 $ 2.21 5.3 years $ 1,012,990 A summary of the status of our unvested restricted stock as of September 30, 2015, and changes during the nine-month period then ended, is presented below: Nine Months Ended September 30, 2015 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 498,250 $ 1.91 Granted 354,000 1.73 Vested (240,750 ) 1.85 Forfeited (108,000 ) 2.71 Unvested at end of period 503,500 $ 1.63 In February 2015, 120,000 shares of restricted stock held by non-employee directors with an aggregate fair value of $193,000 vested as scheduled according to the terms of the restricted stock agreements. In March 2015, 20,000 shares of restricted stock held by an employee with an aggregate fair value of $33,000 vested as scheduled according to the terms of a restricted stock agreement. In May 2015, 100,750 shares of restricted stock held by employees with an aggregate fair value of $130,000 vested as scheduled according to the terms of the restricted stock agreements. As of September 30, 2015, there was approximately $1.5 million of total unrecognized compensation expense related to unvested stock-based awards, which we expect to recognize over the remaining weighted average vesting term of 1.7 years.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	4. Earnings (Loss) Per Share Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares and, except for periods with a loss from operations, participating securities outstanding during the period. Diluted earnings (loss) per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may be issued by the Company include convertible debt, convertible preferred stock, options and warrants. Diluted earnings (loss) per common share for the three-month and nine-month periods ended September 30, 2015 and 2014 excludes the effects of 19.3 million and 17.7 million common share equivalents, respectively, since such inclusion would be anti-dilutive. The excluded shares consist of common shares issuable upon exercise of outstanding stock options and warrants, and upon the conversion of convertible debt and convertible preferred stock. The Company’s unvested stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 503,500 shares of unvested restricted stock for the three-month and nine-month periods ended September 30, 2015, and 563,500 shares of unvested restricted stock for the three-month and nine-month periods ended September 30, 2014, respectively, were excluded in determining basic and diluted loss per share because such inclusion would be anti-dilutive.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventory	5. Inventory All components of inventory are valued at the lower of cost (first-in, first-out) or market. We adjust inventory to market value when the net realizable value is lower than the carrying cost of the inventory. Market value is determined based on estimated sales activity and margins. The components of inventory as of September 30, 2015 and December 31, 2014, net of reserves of $352,000 and $539,000, respectively, are as follows: September 30, 2015 December 31, 2014 (unaudited) Materials $ 396,000 $ — Work-in-process 236,422 1,034,476 Finished goods 596,450 436,936 Reserves (351,689 ) (539,027 ) Total $ 877,183 $ 932,385 During the nine-month period ended September 30, 2015, we capitalized $810,000 of inventory costs associated with our Lymphoseek product. The Company capitalized no such costs during the same period in 2014. During the nine-month period ended September 30, 2015, we wrote off $120,000 of materials related to production issues. During the nine-month periods ended September 30, 2015 and 2014, we utilized $184,000 and $121,000, respectively, of previously capitalized Lymphoseek inventory due to the consumption of the Lymphoseek material for product testing and development purposes. We estimate a reserve for obsolete inventory based on management’s judgment of probable future commercial use, which is based on an analysis of current inventory levels, estimated future sales and production rates, and estimated shelf lives.

Investment in Macrophage Therap

Investment in Macrophage Therapeutics, Inc.	9 Months Ended
	Sep. 30, 2015
Investments In And Advances To Affiliates Schedule Of Investments [Abstract]
Investment in Macrophage Therapeutics, Inc.	6. Investment in Macrophage Therapeutics, Inc. In March 2015, MT, our previously wholly-owned subsidiary, entered into a Securities Purchase Agreement to sell up to 50 shares of its Series A Convertible Preferred Stock (MT Preferred Stock) and warrants to purchase up to 1,500 common shares of MT (MT Common Stock) to Platinum-Montaur Life Sciences, LLC (Platinum) and Dr. Michael Goldberg (collectively, the Investors) for a purchase price of $50,000 per unit. A unit consists of one share of MT Preferred Stock and 30 warrants to purchase MT Common Stock. Under the agreement, 40% of the MT Preferred Stock and warrants are committed to be purchased by Dr. Goldberg, and the balance by Platinum. The full 50 shares of MT Preferred Stock and warrants that may be sold under the agreement are convertible into, and exercisable for, MT Common Stock representing an aggregate 1% interest on a fully converted and exercised basis. Navidea owns the remainder of the MT Common Stock. On March 11, 2015, definitive agreements with the Investors were signed for the sale of the first tranche of 10 shares of MT Preferred Stock and warrants to purchase 300 shares of MT Common Stock to the Investors, with gross proceeds to MT of $500,000. The MT Common Stock held by parties other than Navidea is reflected on the consolidated balance sheets as a noncontrolling interest. The warrants have certain characteristics including a net settlement provision that require the warrants to be accounted for as a derivative liability at fair value, with subsequent changes in fair value included in earnings. The fair value of the warrants was estimated to be $63,000 at issuance and at September 30, 2015. See Notes 1(b)(3) and 2. In addition, the MT Preferred Stock includes a beneficial conversion feature. The conversion option was immediately convertible upon issuance, resulting in a deemed dividend of $46,000 related to the beneficial conversion feature. Finally, certain provisions of the Securities Purchase Agreement obligate the Investors to acquire the remaining MT Preferred Stock and related warrants for $2.0 million at the option of MT. The estimated relative fair value of this put option was $113,000 at issuance based on the Black-Scholes option pricing model and is classified within stockholders' equity. In addition, we entered into a Securities Exchange Agreement with the Investors providing them an option to exchange their MT Preferred Stock for our common stock in the event that MT has not completed a public offering with gross proceeds to MT of at least $50 million by the second anniversary of the closing of the initial sale of MT Preferred Stock, at an exchange rate per share obtained by dividing $50,000 by the greater of (i) 80% of the twenty-day volume weighted average price per share of our common stock on the second anniversary of the initial closing or (ii) $3.00. To the extent that the Investors do not timely exercise their exchange right, MT has the right to redeem their MT Preferred Stock for a price equal to $58,320 per share. We also granted MT an exclusive license for certain therapeutic applications of the Manocept technology.

Investment in R-NAV, LLC

Investment in R-NAV, LLC	9 Months Ended
	Sep. 30, 2015
Equity Method Investments And Joint Ventures [Abstract]
Investment in R-NAV, LLC	7. Investment in R-NAV, LLC Navidea’s investment in R-NAV, LLC (R-NAV) of approximately 31% is being accounted for using the equity method of accounting. Navidea’s equity in the loss of R-NAV was $27,000 and $262,000, respectively, for the three-month periods ended September 30, 2015 and 2014. Navidea’s equity in the loss of R-NAV was $295,000 and $262,000, respectively, for the nine-month periods ended September 30, 2015 and 2014. The Company’s obligation to provide $500,000 of in-kind services to R-NAV is being recognized as those services are provided. The Company provided $27,000 and $21,000, respectively, of in-kind services during the three-month periods ended September 30, 2015 and 2014. The Company provided $54,000 and $21,000, respectively, of in-kind services during the nine-month periods ended September 30, 2015 and 2014. As of September 30, 2015, the Company has $408,000 of in-kind services remaining to provide under this obligation.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Notes Payable	8. Notes Payable Capital Royalty Group Debt In May 2015, Navidea and its subsidiary Macrophage Therapeutics, Inc., as guarantor, executed a Term Loan Agreement (the CRG Loan Agreement) with Capital Royalty Partners II L.P. in its capacity as a lender and as control agent for other affiliated lenders party to the CRG Loan Agreement (collectively, the Lenders) in which the Lenders agreed to make a term loan to the Company in the aggregate principal amount of $50 million (the CRG Term Loan), with an additional $10 million in loans to be made available upon the satisfaction of certain conditions stated in the CRG Loan Agreement. Closing and funding of the CRG Term Loan occurred on May 15, 2015 (the Effective Date). The principal balance of the CRG Term Loan will bear interest from the Effective Date at a per annum rate of interest equal to 14.0%. Through March 31, 2019, the Company has the option of paying (i) 10.00% of the per annum interest in cash and (ii) 4.00% of the per annum interest as compounded interest which is added to the aggregate principal amount of the CRG Term Loan. During the nine-month period ended September 30, 2015, $769,000 of interest was compounded and added to the balance of the CRG Term Loan. In addition, the Company began paying the cash portion of the interest in arrears on June 30, 2015. Principal is due in eight equal quarterly installments during the final two years of the term. All unpaid principal, and accrued and unpaid interest, is due and payable in full on March 31, 2021. As of September 30, 2015, the outstanding principal balance of the CRG Term Loan was $50.8 million. The Company may voluntarily prepay the CRG Term Loan in full, upon fifteen business days’ prior written notice to the Lenders, with a prepayment premium beginning at 5% and declining by 1% annually thereafter, with no premium being payable if prepayment occurs after the fifth year of the term. The CRG Term Loan required the payment on the borrowing date of a financing fee of $625,000 which was recorded as a discount to the debt. In addition, a facility fee of $1.0 million is payable at the end of the term or when the loan is repaid in full. A long-term liability has been recorded for the $1.0 million facility fee with a corresponding discount to the debt. The CRG Term Loan is collateralized by a security interest in substantially all of the Company's assets. The CRG Loan Agreement requires that the Company adhere to certain affirmative and negative covenants, including financial reporting requirements and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the CRG Loan Agreement. The Lenders may accelerate the payment terms of the CRG Loan Agreement upon the occurrence of certain events of default set forth therein, which include the failure of the Company to make timely payments of amounts due under the CRG Loan Agreement, the failure of the Company to adhere to the covenants set forth in the CRG Loan Agreement, and the insolvency of the Company. The covenants of the CRG Loan Agreement include a covenant that the Company shall have EBITDA of no less than $5 million in each calendar year during the term or revenues from sales of Lymphoseek in each calendar year during the term of at least $11 million in 2015, with the target minimum revenue increasing in each year thereafter until reaching $45 million in 2020. The Company believes it is still possible to achieve the level of sales required to maintain compliance with the sales covenant. However, if the Company were to fail to meet the applicable minimum EBITDA or revenue target in any calendar year, the CRG Loan Agreement provides the Company a cure right if it raises 2.5 times the EBITDA or revenue shortfall in equity or subordinated debt and deposits such funds in a separate blocked account. The Company is confident it has the ability to access the capital necessary to cure any potential shortfall for 2015. Additionally, the Company must maintain liquidity, defined as the balance of unencumbered cash and permitted cash equivalent investments, of at least $5 million during the term of the CRG Term Loan. The events of default under the CRG Loan Agreement also include a failure of Platinum to perform its funding obligations under the Platinum Loan Agreement (as defined below) at any time as to which the Company had negative EBITDA for the most recent fiscal quarter, as a result either of Platinum’s repudiation of its obligations under the Platinum Loan Agreement, or the occurrence of an insolvency event with respect to Platinum. As of September 30, 2015, we were in compliance with all applicable covenants of the CRG Loan Agreement. In connection with the CRG Loan Agreement, the Company recorded a debt discount related to lender fees and other costs directly attributable to the CRG Loan Agreement totaling $2.2 million. The debt discount is being amortized as non-cash interest expense using the effective interest method over the term of the CRG Loan Agreement. As of September 30, 2015, the balance of the debt discount was $2.1 million. Oxford Debt In March 2014, we executed a Loan and Security Agreement (the Oxford Loan Agreement) with Oxford Finance, LLC (Oxford), providing for a loan to the Company of $30 million. Pursuant to the Oxford Loan Agreement, we issued Oxford: (1) Term Notes in the aggregate principal amount of $30 million, bearing interest at 8.5% (the Oxford Notes), and (2) Series KK warrants to purchase an aggregate of 391,032 shares of our common stock at an exercise price of $1.918 per share, expiring in March 2021 (the Series KK warrants). We began making monthly payments of interest only on April 1, 2014, and monthly payments of principal and interest beginning April 1, 2015. In May 2015, in connection with the consummation of the CRG Loan Agreement, the Company repaid all amounts outstanding under the Oxford Loan Agreement. The payoff amount of $31.6 million included payments of $289,000 as a pre-payment fee and $2.4 million as an end-of-term final payment fee. The carrying value of the Oxford Notes was $26.9 million prior to payoff. We recorded a loss on extinguishment of the Oxford Notes of $2.4 million. Platinum Credit Facility In connection with the Company entering into the CRG Loan Agreement, the Company and Platinum entered into a Third Amendment (the Third Platinum Amendment) to the Loan Agreement between the Company and Platinum, dated July 25, 2012, as amended June 25, 2013 and March 4, 2014 (the Platinum Loan Agreement). Platinum and the Lenders also entered into a Subordination Agreement (the Subordination Agreement), which the Company consented to and acknowledged, providing for the subordination of the Company’s indebtedness to Platinum under the Platinum Loan Agreement to the Company’s indebtedness under the CRG Loan Agreement, among other customary terms and conditions. Contemporaneously with the execution of the Third Platinum Amendment, the Company delivered a Third Amended and Restated Promissory Note, dated the Effective Date (the Third Amended Platinum Note), which amends and restates the Second Amended Promissory Note, dated March 4, 2014, made by the Company in favor of Platinum in the original principal amount of up to $35 million. Among other things, the Third Platinum Amendment (i) extends the term of the Platinum Loan Agreement until September 30, 2021 or six months following an early repayment of the CRG Term Loan; (ii) changes the interest rate to the greater of (a) the United States prime rate as reported in The Wall Street Journal plus 6.75%, (b) 10.0% or (c) the highest rate of interest then payable pursuant to the CRG Term Loan plus 0.125% (the effective interest rate as of September 30, 2015 was 14.125%); (iii) requires such interest to compound monthly; and (iv) changes the provisions of the Platinum Loan Agreement governing Platinum’s right to convert advances into common stock of the Company. The Third Platinum Amendment provides for the conversion of all principal and interest outstanding under the Platinum Loan Agreement, but not until such time as the average daily volume weighted average price of the Company’s common stock for the ten preceding trading days exceeds $2.53 per share. The Platinum Loan Agreement provides us with a credit facility of up to $50 million. The Company borrowed an additional $4.5 million under the Platinum Loan Agreement during the nine-month period ended September 30, 2015. In addition, $462,000 of interest was compounded and added to the balance of the Third Amended Platinum Note during the nine-month period ended September 30, 2015. The Third Amended Platinum Note is reflected on the consolidated balance sheets at its estimated fair value, which includes the estimated fair value of the embedded conversion option of $4.1 million. Changes in the estimated fair value of the Third Amended Platinum Note of $1.6 million and $402,000, respectively, were recorded as non-cash changes in fair value of financial instruments during the three-month periods ended September 30, 2015 and 2014. Changes in the estimated fair value of the Third Amended Platinum Note of $1.7 million and $104,000, respectively, were recorded as non-cash changes in fair value of financial instruments during the nine-month periods ended September 30, 2015 and 2014. The estimated fair value of the Third Amended Platinum Note was $12.3 million as of September 30, 2015. As of September 30, 2015, the outstanding principal balance of the Third Amended Platinum Note was approximately $8.2 million, with $27.3 million currently available under the credit facility. An additional $15 million is potentially available under the credit facility on terms to be negotiated. R-NAV Debt In July 2015, we made a principal payment on the note payable to R-NAV of $333,333. As of September 30, 2015, the outstanding principal balance of the note payable to R-NAV was $333,333 which is due in July 2016. Interest on our Debt During the three-month periods ended September 30, 2015 and 2014, we recorded interest expense of $2.2 million and $921,000, respectively, related to our notes payable. Of these amounts, $65,000 and $201,000, respectively, related to amortization of the debt discounts related to our notes payable. An additional $802,000 of total interest expense was compounded and added to the balance of our notes payable during the three-month period ended September 30, 2015. During the nine-month periods ended September 30, 2015 and 2014, we recorded interest expense of $4.7 million and $2.8 million, respectively, related to our notes payable. Of these amounts, $424,000 and $638,000, respectively, related to amortization of the debt discounts related to our notes payable. An additional $1.2 million of total interest expense was compounded and added to the balance of our notes payable during the nine-month period ended September 30, 2015.

Equity

Equity	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Equity	9 . Equity During the nine-month period ended September 30, 2015, we issued 72,476 shares of our common stock valued at $131,000 to certain members of our Board of Directors as payment in lieu of cash for a portion of their fourth quarter 2014 and second quarter 2015 compensation.

Stock Warrants

Stock Warrants	9 Months Ended
	Sep. 30, 2015
Warrants And Rights Note Disclosure [Abstract]
Stock Warrants	10. Stock Warrants In July 2015, we extended the expiration date of our outstanding Series BB warrants by three years to July 2018. The modification of the Series BB warrant expiry resulted in recording a non-cash selling, general and administrative expense of approximately $150,000 during the three-month period ended September 30, 2015. In August 2015, we entered into a Securities Exchange Agreement with two investment funds managed by Platinum Management (NY) LLC to exchange the 4,519 shares of Series B Convertible Preferred Stock (Preferred Stock) held by them for twenty-year warrants to purchase common stock of the Company (the Series LL warrants). The Preferred Stock was convertible into common stock at a conversion rate of 3,270 shares of common stock per share of Preferred Stock resulting in an aggregate number of shares of common stock into which the Preferred Stock was convertible of 14,777,130 shares. The exercise price of the Series LL warrants is $0.01 per share, and the total number of shares of common stock for which the Series LL warrants are exercisable is 14,777,130 shares. The Series LL warrants contain cashless exercise provisions, and the other economic terms are comparable to those of the Preferred Stock, except that there is no liquidation preference associated with the Series LL warrants or shares issuable on the exercise thereof. The Securities Exchange Agreement also contains certain provisions that prohibit the payment of dividends, distributions of common stock or issuances of common stock at effective prices less than $1.35. There was no other consideration paid or received for the exchange. No gain or loss was recognized in our consolidated financial statements as a result of the exchange. The exchange transaction was entered into in connection with the filing of an application to list the Company’s common stock on the Tel Aviv Stock Exchange (TASE) in order to comply with a listing requirement of the TASE requiring that listed companies have only one class of equity securities issued and outstanding. Following the exchange, the Company has no shares of preferred stock outstanding. In September 2015, we issued four-year Series MM warrants to purchase 150,000 shares of our common stock at an exercise price of $2.50 per share pursuant to an advisory services agreement with Chardan Capital Markets, LLC (Chardan). Warrants to purchase an additional 150,000 shares of our common stock on the same terms are issuable to Chardan if they meet certain performance goals as outlined in the agreement. The fair value of the warrants issued and issuable to Chardan of $256,000 was recorded as a non-cash selling, general and administrative expense during the three-month period ended September 30, 2015. At September 30, 2015, there are 16.6 million warrants outstanding to purchase Navidea's common stock. The warrants are exercisable at prices ranging from $0.01 to $3.04 per share with a weighted average exercise price of $0.25 per share. The warrants have remaining outstanding terms ranging from 0 to 20 years. In addition, at September 30, 2015, there are 300 warrants outstanding to purchase MT Common Stock. The warrants are exercisable at $2,000 per share.

Reduction in Force

Reduction in Force	9 Months Ended
	Sep. 30, 2015
Restructuring And Related Activities [Abstract]
Reduction in Force	11. Reduction in Force In March 2015, the Company initiated a reduction in force that included seven staff members and three executives. The executives continued as employees during transition periods of varying lengths, depending upon the nature and extent of responsibilities transitioned or wound down. During the nine-month period ended September 30, 2015, the Company recognized approximately $1.3 million of net expense as a result of the reduction in force, which includes actual and estimated separation costs as well as the impact of accelerated vesting or forfeiture of certain equity awards resulting from the separation of $273,000. A summary of changes in accrued separation costs during the nine-month period ended September 30, 2015 is presented below: Accrued separation costs, December 31, 2014 $ 449,351 Payments related to May 2014 reduction in force (409,947 ) Charges incurred with March 2015 reduction in force 994,572 Payments related to March 2015 reduction in force (994,572 ) Accrued separation costs, September 30, 2015 $ 39,404 The remaining accrued separation costs related to the Company's reductions in force represent the estimated cost of continuing healthcare coverage, and are included in accrued liabilities and other on the consolidated balance sheet as of September 30, 2015.

Termination of Sublicense

Termination of Sublicense	9 Months Ended
	Sep. 30, 2015
Termination Of Sublicense Disclosure [Abstract]
Termination of Sublicense	12. Termination of Sublicense In April 2015, the Company entered into an agreement with Alseres Pharmaceuticals, Inc. (Alseres) to terminate the sub-license agreement dated July 31, 2012 for research, development and commercialization of NAV5001. Under the terms of this agreement, Navidea will transfer all regulatory, clinical and manufacturing-related data related to NAV5001 to Alseres. Alseres will reimburse Navidea for any incurred maintenance costs of the contract manufacturer retroactive to March 1, 2015. In addition, as requested by Alseres, Navidea will supply clinical support services for NAV5001 on a cost-plus reimbursement basis. In consideration for the rights granted to Alseres, Navidea will also receive a milestone payment upon clearance to market NAV5001 by the U.S. FDA and a royalty on subsequent net sales of NAV5001.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Due to the uncertainty surrounding the realization of the deferred tax assets in future tax returns, all of the deferred tax assets have been fully offset by a valuation allowance at September 30, 2015 and December 31, 2014. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no liability for uncertain tax positions was recorded as of September 30, 2015 or December 31, 2014 and we do not expect any significant changes in the next twelve months. Should we need to accrue interest or penalties on uncertain tax positions, we would recognize the interest as interest expense and the penalties as a selling, general and administrative expense. As of September 30, 2015, tax years 2011-2014 remained subject to examination by federal and state tax authorities.

Segments

Segments	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segments	14. Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no inter-segment sales. Prior to 2015, our products and development programs were all related to diagnostic substances. Our majority-owned subsidiary, Macrophage Therapeutics, Inc., was formed and received initial funding during the first quarter of 2015, which resulted in a re-evaluation of the Company's segment determination. We now manage our business based on two primary types of drug products: (i) diagnostic substances, including Lymphoseek and other diagnostic applications of our Manocept platform, our R-NAV subsidiary, NAV4694 and NAV5001, and (ii) therapeutic development programs, including therapeutic applications of our Manocept platform and all development programs undertaken by Macrophage Therapeutics, Inc. The information in the following tables is derived directly from each reportable segment’s financial reporting. Three Months Ended September 30, 2015 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States 1 $ 2,942,498 $ — $ — $ 2,942,498 International 10,024 — — 10,024 Lymphoseek license revenue 550,000 — — 550,000 Grant and other revenue 476,755 — — 476,755 Total revenue 3,979,277 — — 3,979,277 Cost of goods sold, excluding depreciation and amortization 442,094 — — 442,094 Research and development expenses, excluding depreciation and amortization 3,603,501 297,137 — 3,900,638 Selling, general and administrative expenses, excluding depreciation and amortization 2 1,063,062 42,487 2,721,844 3,827,393 Depreciation and amortization 3 17,013 — 115,216 132,229 Loss from operations 4 (1,146,393 ) (339,624 ) (2,837,060 ) (4,323,077 ) Other income (expense), excluding equity in the loss of R-NAV, LLC 5 — — (3,721,242 ) (3,721,242 ) Equity in the loss of R-NAV, LLC — — (26,785 ) (26,785 ) Net loss (1,146,393 ) (339,624 ) (6,585,087 ) (8,071,104 ) Total assets, net of depreciation and amortization: United States 3,750,702 — 13,291,939 17,042,641 International 440,349 — 467 440,816 Capital expenditures — — 2,788 2,788 Nine Months Ended September 30, 2015 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States 1 $ 6,736,418 $ — $ — $ 6,736,418 International 15,074 — — 15,074 Lymphoseek license revenue 883,333 — — 883,333 Grant and other revenue 1,320,816 — — 1,320,816 Total revenue 8,955,641 — — 8,955,641 Cost of goods sold, excluding depreciation and amortization 1,167,141 — — 1,167,141 Research and development expenses, excluding depreciation and amortization 9,610,012 559,888 — 10,169,900 Selling, general and administrative expenses, excluding depreciation and amortization 2 4,634,279 120,872 8,381,910 13,137,061 Depreciation and amortization 3 207,498 — 223,870 431,368 Loss from operations 4 (6,663,289 ) (680,760 ) (8,605,780 ) (15,949,829 ) Other income (expense), excluding equity in the loss of R-NAV, LLC 5 — — (8,808,202 ) (8,808,202 ) Equity in the loss of R-NAV, LLC — — (295,217 ) (295,217 ) Net loss (6,663,289 ) (680,760 ) (17,709,199 ) (25,053,248 ) Total assets, net of depreciation and amortization: United States 3,750,702 — 13,291,939 17,042,641 International 440,349 — 467 440,816 Capital expenditures 25,492 — 4,914 30,406 1 All sales to Cardinal Health are made in the United States; Cardinal distributes the product throughout the U.S. through its network of nuclear pharmacies. 2 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments. Marketing and selling expenses are allocated to our individual reportable segments. 3 4 Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments. 5 Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.

Supplemental Disclosure for Sta

Supplemental Disclosure for Statements of Cash Flows	9 Months Ended
	Sep. 30, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure for Statements of Cash Flows	15. Supplemental Disclosure for Statements of Cash Flows During the nine-month periods ended September 30, 2015 and 2014, we paid interest aggregating $3.3 million and $2.1 million, respectively. During the nine-month periods ended September 30, 2015 and 2014, we recorded $1.0 million and $2.4 million, respectively, of end-of-term fees associated with our notes payable to CRG and Oxford. In connection with their initial investment in March 2015, the investors in MT were issued warrants that have been determined to be derivative liabilities with an estimated fair value of $63,000. A $46,000 deemed dividend related to the beneficial conversion feature within the MT Preferred Stock was also recorded at the time of the initial investment in MT.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policy)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	a. Basis of Presentation : The information presented as of September 30, 2015 and for the three-month and nine-month periods ended September 30, 2015 and 2014 is unaudited, but includes all adjustments (which consist only of normal recurring adjustments) that the management of Navidea Biopharmaceuticals, Inc. (Navidea, the Company, or we) believes to be necessary for the fair presentation of results for the periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The balances as of September 30, 2015 and the results for the interim periods are not necessarily indicative of results to be expected for the year. The consolidated financial statements should be read in conjunction with Navidea’s audited consolidated financial statements for the year ended December 31, 2014, which were included as part of our Annual Report on Form 10-K. Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Limited and Cardiosonix Ltd, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (MT). All significant inter-company accounts were eliminated in consolidation. Navidea's investment in R-NAV, LLC (R-NAV) is being accounted for using the equity method of accounting and is therefore not consolidated.
Financial Instruments and Fair Value	b. Financial Instruments and Fair Value: In accordance with current accounting standards, the fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value, giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2 – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In determining the appropriate levels, we perform a detailed analysis of the assets and liabilities whose fair value is measured on a recurring basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 2. The following methods and assumptions were used to estimate the fair value of each class of financial instruments: (1) Cash, accounts receivable, accounts payable, and accrued liabilities: The carrying amounts approximate fair value because of the short maturity of these instruments. (2) Notes payable: The carrying value of our debt at September 30, 2015 and December 31, 2014 primarily consists of the face amount of the notes less unamortized discounts. See Note 8. At September 30, 2015 and December 31, 2014, certain notes payable were also required to be recorded at fair value. The estimated fair value of our debt was calculated using a discounted cash flow analysis as well as a Monte Carlo simulation. These valuation methods include Level 3 inputs such as the estimated current market interest rate for similar instruments with similar creditworthiness. For the debt recorded at fair value, unrealized gains and losses on the fair value of the debt are classified in other expenses as a change in the fair value of financial instruments in the consolidated statements of operations. At September 30, 2015, the fair value of our notes payable is approximately $64.2 million, compared to the carrying value of $61.3 million. (3) Derivative liabilities: Derivative liabilities are related to certain outstanding warrants which are recorded at fair value. Derivative liabilities totaling $63,000 as of September 30, 2015 were included in other liabilities on the consolidated balance sheets. No derivative liabilities were outstanding as of December 31, 2014. The assumptions used to calculate fair value as of September 30, 2015 included volatility, a risk-free rate and expected dividends. In addition, we considered non-performance risk and determined that such risk is minimal. Unrealized gains and losses on the derivatives are classified in other expenses as a change in the fair value of financial instruments in the statements of operations. See Notes 2 and 6.
Revenue Recognition	c. Revenue Recognition: We currently generate revenue primarily from sales of Lymphoseek ® We earn additional revenues based on a percentage of the actual net revenues achieved by Cardinal Health on sales to end customers made during each fiscal year. The amount we charge Cardinal Health related to end customer sales of Lymphoseek are subject to a retroactive annual adjustment. To the extent that we can reasonably estimate the end-customer prices received by Cardinal Health, we record sales based upon these estimates at the time of sale. If we are unable to reasonably estimate end customer sales prices related to products sold, we record revenue related to these product sales at the minimum (i.e., floor) price provided for under our distribution agreement with Cardinal Health. We also earn revenues related to our licensing and distribution agreements. The terms of these agreements may include payment to us of non-refundable upfront license fees, funding or reimbursement of research and development efforts, milestone payments if specified objectives are achieved, and/or royalties on product sales. We evaluate all deliverables within an arrangement to determine whether or not they provide value on a stand-alone basis. We recognize a contingent milestone payment as revenue in its entirety upon our achievement of a substantive milestone if the consideration earned from the achievement of the milestone (i) is consistent with performance required to achieve the milestone or the increase in value to the delivered item, (ii) relates solely to past performance and (iii) is reasonable relative to all of the other deliverables and payments within the arrangement. We received a non-refundable upfront cash payment of $2.0 million from SpePharm AG upon execution of the SpePharm License Agreement in March 2015. We have determined that the license and other non-contingent deliverables do not have stand-alone value because the license could not be deemed to be fully delivered for its intended purpose unless we perform our other obligations, including specified development work. Accordingly, they do not meet the separation criteria, resulting in these deliverables being considered a single unit of account. As a result, revenue relating to the upfront cash payment was deferred and is being recognized on a straight-line basis over the estimated obligation period of two years. We generate additional revenue from grants to support various product development initiatives. We generally recognize grant revenue when expenses reimbursable under the grants have been paid and payments under the grants become contractually due. Lastly, we recognize revenues from the provision of services to R-NAV and its subsidiaries. See Note 7.
Change in Accounting Principle and Recent Accounting Pronouncements	d. Change in Accounting Principle: In April 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-03, Simplifying the Presentation of Debt Issuance Costs . ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability rather than as an asset. The recognition and measurement guidance for debt issuance costs are not affected by ASU 2015-03. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted. Entities must apply the amendments in ASU 2015-03 on a retrospective basis. During the second quarter of 2015, the Company elected early adoption of ASU 2015-03. The consolidated balance sheet as of December 31, 2014 has been adjusted to reflect retrospective application of the new method of presentation. Deferred debt issuance costs totaling $90,000 that were included in other assets as of December 31, 2014 were reclassified as discounts on notes payable, current, of $35,000 and discounts on notes payable, long term, of $55,000. We have reflected these unamortized costs as a reduction of the debt on the balance sheet as of September 30, 2015 and will continue to do so in future periods. The adoption of ASU 2015-03 had no impact on the consolidated statements of operations, stockholders' deficit or cash flows. e. Recent Accounting Pronouncements: In February 2015, the FASB issued ASU No. 2015-02, Amendments to the Consolidation Analysis . ASU 2015-02 affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. All legal entities are subject to reevaluation under the revised consolidation model. Specifically, the amendments: (i) modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities, (ii) eliminate the presumption that a general partner should consolidate a limited partnership, and (iii) affect the consolidation analysis of reporting entities that are involved with VIEs, particularly those that have fee arrangements and related party relationships. ASU 2015-02 is effective for public entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The amendments may be applied using a modified retrospective approach or a full retrospective approach. Early adoption is permitted, including adoption in an interim period. We are currently evaluating the impact of our adoption of ASU 2015-02, however we do not expect the adoption of ASU 2015-02 to have a material effect on our consolidated financial statements upon adoption. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Liabilities Measured on Recurring Basis	The following tables set forth, by level, financial liabilities measured at fair value on a recurring basis: Liabilities Measured at Fair Value on a Recurring Basis as of September 30, 2015 Description Quoted Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Platinum notes payable $ — $ — $ 12,280,513 $ 12,280,513 Liability related to warrants — — 63,000 63,000 Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2014 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Platinum notes payable $ — $ — $ 5,615,764 $ 5,615,764

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Options Activity	A summary of the status of our stock options as of September 30, 2015, and changes during the nine-month period then ended, is presented below: Nine Months Ended September 30, 2015 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at beginning of period 5,345,764 $ 2.16 Granted 1,365,400 1.67 Exercised (146,625 ) 0.61 Canceled and Forfeited (1,081,725 ) 2.82 Expired (5,750 ) 1.26 Outstanding at end of period 5,477,064 $ 1.95 7.4 years $ 3,058,790 Exercisable at end of period 2,222,049 $ 2.21 5.3 years $ 1,012,990
Schedule of Nonvested Restricted Stock Activity	A summary of the status of our unvested restricted stock as of September 30, 2015, and changes during the nine-month period then ended, is presented below: Nine Months Ended September 30, 2015 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 498,250 $ 1.91 Granted 354,000 1.73 Vested (240,750 ) 1.85 Forfeited (108,000 ) 2.71 Unvested at end of period 503,500 $ 1.63

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	The components of inventory as of September 30, 2015 and December 31, 2014, net of reserves of $352,000 and $539,000, respectively, are as follows: September 30, 2015 December 31, 2014 (unaudited) Materials $ 396,000 $ — Work-in-process 236,422 1,034,476 Finished goods 596,450 436,936 Reserves (351,689 ) (539,027 ) Total $ 877,183 $ 932,385

Reduction in Force (Tables)

Reduction in Force (Tables)	9 Months Ended
	Sep. 30, 2015
Restructuring And Related Activities [Abstract]
Restructuring and related costs	A summary of changes in accrued separation costs during the nine-month period ended September 30, 2015 is presented below: Accrued separation costs, December 31, 2014 $ 449,351 Payments related to May 2014 reduction in force (409,947 ) Charges incurred with March 2015 reduction in force 994,572 Payments related to March 2015 reduction in force (994,572 ) Accrued separation costs, September 30, 2015 $ 39,404

Segments (Tables)

Segments (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Schedule of segment reporting information	The information in the following tables is derived directly from each reportable segment’s financial reporting. Three Months Ended September 30, 2015 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States 1 $ 2,942,498 $ — $ — $ 2,942,498 International 10,024 — — 10,024 Lymphoseek license revenue 550,000 — — 550,000 Grant and other revenue 476,755 — — 476,755 Total revenue 3,979,277 — — 3,979,277 Cost of goods sold, excluding depreciation and amortization 442,094 — — 442,094 Research and development expenses, excluding depreciation and amortization 3,603,501 297,137 — 3,900,638 Selling, general and administrative expenses, excluding depreciation and amortization 2 1,063,062 42,487 2,721,844 3,827,393 Depreciation and amortization 3 17,013 — 115,216 132,229 Loss from operations 4 (1,146,393 ) (339,624 ) (2,837,060 ) (4,323,077 ) Other income (expense), excluding equity in the loss of R-NAV, LLC 5 — — (3,721,242 ) (3,721,242 ) Equity in the loss of R-NAV, LLC — — (26,785 ) (26,785 ) Net loss (1,146,393 ) (339,624 ) (6,585,087 ) (8,071,104 ) Total assets, net of depreciation and amortization: United States 3,750,702 — 13,291,939 17,042,641 International 440,349 — 467 440,816 Capital expenditures — — 2,788 2,788 Nine Months Ended September 30, 2015 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States 1 $ 6,736,418 $ — $ — $ 6,736,418 International 15,074 — — 15,074 Lymphoseek license revenue 883,333 — — 883,333 Grant and other revenue 1,320,816 — — 1,320,816 Total revenue 8,955,641 — — 8,955,641 Cost of goods sold, excluding depreciation and amortization 1,167,141 — — 1,167,141 Research and development expenses, excluding depreciation and amortization 9,610,012 559,888 — 10,169,900 Selling, general and administrative expenses, excluding depreciation and amortization 2 4,634,279 120,872 8,381,910 13,137,061 Depreciation and amortization 3 207,498 — 223,870 431,368 Loss from operations 4 (6,663,289 ) (680,760 ) (8,605,780 ) (15,949,829 ) Other income (expense), excluding equity in the loss of R-NAV, LLC 5 — — (8,808,202 ) (8,808,202 ) Equity in the loss of R-NAV, LLC — — (295,217 ) (295,217 ) Net loss (6,663,289 ) (680,760 ) (17,709,199 ) (25,053,248 ) Total assets, net of depreciation and amortization: United States 3,750,702 — 13,291,939 17,042,641 International 440,349 — 467 440,816 Capital expenditures 25,492 — 4,914 30,406 1 All sales to Cardinal Health are made in the United States; Cardinal distributes the product throughout the U.S. through its network of nuclear pharmacies. 2 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments. Marketing and selling expenses are allocated to our individual reportable segments. 3 4 Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments. 5 Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)	1 Months Ended	9 Months Ended
	Mar. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Accounting Policies [Line Items]
Notes payable		$ 61,300,000
Fair value of notes payable		64,200,000
Derivative liabilities		$ 63,000	$ 0
Non-refundable upfront cash payment received	$ 2,000,000
Deferred revenue recognition period		2 years
Deferred debt issuance cost			90,000
Notes Payable Current
Accounting Policies [Line Items]
Notes payable, discounts		$ 0	863,813
Notes Payable Current | New Accounting Pronouncement, Early Adoption, Effect
Accounting Policies [Line Items]
Notes payable, discounts		35,000
Notes Payable Non Current
Accounting Policies [Line Items]
Notes payable, discounts		2,102,947	$ 1,585,882
Notes Payable Non Current | New Accounting Pronouncement, Early Adoption, Effect
Accounting Policies [Line Items]
Notes payable, discounts		$ 55,000

Fair Value (Narrative) (Details

Fair Value (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 11, 2015	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Derivative liabilities	$ 63,000		$ 63,000			$ 0
Macrophage Therapeutics | Common Stock
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Number of shares underlying warrant issued	300		300		300
Macrophage Therapeutics | Convertible Preferred Stock
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Preferred stock issued					10
Recurring
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Platinum notes payable	$ 12,280,513		$ 12,280,513			5,615,764
Derivative liabilities	63,000		63,000
Transfers into Level 2	0	$ 0	0	$ 0
Transfers out of Level 2	0	0	0	0
Recurring | Quoted Prices in Active Markets for Identical Liabilities (Level 1)
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Liabilities at fair value	0	0	0	0
Recurring | Significant Unobservable Inputs (Level 3)
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Platinum notes payable	12,280,513		12,280,513			$ 5,615,764
Derivative liabilities	63,000		63,000
Change in fair value of Level 3 liabilities	$ 1,600,000	$ 410,000	$ 1,700,000	$ 109,000

Fair Value (Financial Liabiliti

Fair Value (Financial Liabilities measured at fair value on a recurring basis) (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liability related to warrants	$ 63,000	$ 0
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Platinum notes payable	12,280,513	5,615,764
Liability related to warrants	63,000
Recurring | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Platinum notes payable	12,280,513	$ 5,615,764
Liability related to warrants	$ 63,000

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details)	1 Months Ended			3 Months Ended		9 Months Ended
	May. 31, 2015USD ($)shares	Mar. 31, 2015USD ($)shares	Feb. 28, 2015USD ($)shares	Sep. 30, 2015USD ($)planshares	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)planshares	Sep. 30, 2014USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock based compensation plans | plan				2		2
Stock compensation expense (reversal) | $				$ 397,000	$ (528,000)	$ 1,900,000	$ 1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period						240,750
Weighted Average Grant-Date Fair Value
Unrecognized compensation expense, Nonvested awards | $				$ 1,500,000		$ 1,500,000
Unrecognized compensation cost, Period for Recognition						1 year 8 months 12 days
The 2002 and 2014 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation, outstanding stock options' expiration period						10 years
Stock based compensation, outstanding stock options' expiration period upon optionee's separation from employment						90 days
The 2002 and 2014 Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation, granted stock options' vesting period						1 year
The 2002 and 2014 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation, granted stock options' vesting period						4 years
Unvested Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	100,750	20,000	120,000
Aggregate fair value of restricted stock vested | $	$ 130,000	$ 33,000	$ 193,000
The 2002 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares authorized				12,000,000		12,000,000
The 2014 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares authorized				5,000,000		5,000,000

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary of Stock Options Activity) (Details)	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Number of Options
Outstanding at beginning of period	5,345,764
Granted	1,365,400
Exercised	(146,625)
Canceled and Forfeited	(1,081,725)
Expired	(5,750)
Outstanding at end of period	5,477,064
Exercisable at end of period	2,222,049
Weighted Average Exercise Price
Outstanding at beginning of period, dollars per share | $ / shares	$ 2.16
Granted, dollars per share | $ / shares	1.67
Exercised, dollars per share | $ / shares	0.61
Canceled and Forfeited, dollars per share | $ / shares	2.82
Expired, dollars per share | $ / shares	1.26
Outstanding at end of period, dollars per share | $ / shares	1.95
Exercisable at end of period, dollars per share | $ / shares	$ 2.21
Weighted Average Remaining Contractual Life (years)
Outstanding at end of period	7 years 4 months 24 days
Exercisable at end of period	5 years 3 months 18 days
Aggregate Intrinsic Value
Outstanding at end of period | $	$ 3,058,790
Exercisable at end of period | $	$ 1,012,990

Stock-Based Compensation (Sum33

Stock-Based Compensation (Summary of Unvested Restricted Stock) (Details)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Number of Shares
Unvested at beginning of period, shares	498,250
Granted, shares	354,000
Vested, shares	(240,750)
Forfeited, shares	(108,000)
Unvested at end of period, shares	503,500
Weighted Average Grant-Date Fair Value
Unvested at beginning of period, USD per share | $ / shares	$ 1.91
Granted, USD per share | $ / shares	1.73
Vested, USD per share | $ / shares	1.85
Forfeited,USD per share | $ / shares	2.71
Unvested at end of period, USD per share | $ / shares	$ 1.63

Earnings (Loss) Per Share (Narr

Earnings (Loss) Per Share (Narrative) (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Stock Options Warrants Convertible Debt And Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded in determining basic and diluted loss per share	19,300,000	17,700,000	19,300,000	17,700,000
Unvested Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded in determining basic and diluted loss per share	503,500	563,500	503,500	563,500

Inventory (Narrative) (Details)

Inventory (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Inventory [Line Items]
Inventory reserves	$ 351,689		$ 539,027
Inventory, cost capitalized during period	810,000	$ 0
Inventory reserves related to production issues and research and development	138,914	539,027
Production Materials
Inventory [Line Items]
Inventory reserves related to production issues and research and development	120,000
In Process Research and Development
Inventory [Line Items]
Inventory reserves related to production issues and research and development	$ 184,000	$ 121,000

Inventory - Components of Inven

Inventory - Components of Inventory, Net of Reserves (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory, Raw Materials, Gross	$ 396,000
Inventory, Work in Process, Gross	236,422	$ 1,034,476
Inventory, Finished Goods, Gross	596,450	436,936
Inventory Valuation Reserves	(351,689)	(539,027)
Total	$ 877,183	$ 932,385

Investment in Macrophage Ther37

Investment in Macrophage Therapeutics, Inc. (Details) - USD ($)	Mar. 11, 2015	Mar. 31, 2015	Mar. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Schedule Of Investments [Line Items]
Derivative liabilities				$ 63,000	$ 0
Deemed dividend on beneficial conversion feature of MT Preferred Stock				46,000
Minimum required proceeds from initial public offering				$ 50,000,000
Weighted average price per share				80.00%
Price per share				$ 3
Dr. Michael Goldberg
Schedule Of Investments [Line Items]
Percentage of preferred stock reserved		40.00%	40.00%
Convertible Preferred Stock
Schedule Of Investments [Line Items]
Preferred stock authorized		50	50
Purchase price per share (USD per share)		$ 50,000	$ 50,000
Proceeds from issuance of convertible preferred stock and warrants	$ 500,000
Deemed dividend on beneficial conversion feature of MT Preferred Stock		$ 46,000
Value of warrants				$ 2,000,000
Put option fair value				113,000
Common stock value				$ 50,000
Macrophage Therapeutics
Schedule Of Investments [Line Items]
Shares authorized upon exercise of warrants		1,500	1,500
Preferred shares, per unit			1
Common stock warrants, per unit			30
Macrophage Therapeutics | Convertible Preferred Stock
Schedule Of Investments [Line Items]
Preferred stock authorized		50	50
Preferred stock issued	10
Deemed dividend on beneficial conversion feature of MT Preferred Stock		$ 46,000
Preferred stock value				$ 58,320
Macrophage Therapeutics | Common Stock
Schedule Of Investments [Line Items]
Common stock as percentage of common equity		1.00%	1.00%
Number of shares underlying warrant issued	300			300

Investment in R-NAV, LLC (Detai

Investment in R-NAV, LLC (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Schedule Of Equity Method Investments [Line Items]
Equity in loss of R-NAV, LLC	$ 26,785	$ 262,198	$ 295,217	$ 262,198
R-NAV
Schedule Of Equity Method Investments [Line Items]
Ownership percentage	31.00%		31.00%
Equity in loss of R-NAV, LLC	$ 27,000	262,000	$ 295,000	262,000
Commitment to provide services	500,000		500,000
Cost of services provided	27,000	$ 21,000	54,000	$ 21,000
Remaining commitment to provide services	$ 408,000		$ 408,000

Notes Payable (Narrative) (Deta

Notes Payable (Narrative) (Details)	1 Months Ended			3 Months Ended		9 Months Ended
	Jul. 31, 2015USD ($)	May. 31, 2015USD ($)	Mar. 31, 2015	Sep. 30, 2015USD ($)$ / shares	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)d$ / shares	Sep. 30, 2014USD ($)	May. 15, 2015USD ($)	Dec. 31, 2014USD ($)	Mar. 31, 2014USD ($)$ / sharesshares
Debt Instrument [Line Items]
Debt Instrument, increase in accrued interest				$ 802,000		$ 1,200,000
Notes payable				61,300,000		61,300,000
End-of-term fee				1,000,000	$ 2,400,000	1,000,000	$ 2,400,000
Loss on extinguishment of debt						(2,440,714)	(2,610,196)
Proceeds from notes payable						54,500,000	30,000,000
Change in fair value of financial instruments				(1,577,275)	(409,650)	(1,702,902)	(109,499)
Repayments of notes payable	$ 333,333					30,333,333	25,000,000
Notes payable, current				333,333		333,333			$ 4,348,678
Interest expense				2,200,000	921,000	4,700,000	2,800,000
Interest expense recorded related to amortization				$ 65,000	201,000	$ 424,000	638,000
Minimum
Debt Instrument [Line Items]
Exercise price of warrant issued, dollars per share | $ / shares				$ 0.01		$ 0.01
CRG Term Loan
Debt Instrument [Line Items]
Debt face amount								$ 50,000,000
Debt Instrument, unused borrowing capacity								$ 10,000,000
Debt instrument, interest rate								14.00%
Debt Instrument, interest rate, paid in cash								10.00%
Debt Instrument, Interest rate, paid-in-kind								4.00%
Frequency of periodic payment of principal amount						eight equal quarterly installments
Payment terms						2 years
Debt Instrument, increase in accrued interest						$ 769,000
Notes payable				$ 50,800,000		$ 50,800,000
Debt instrument, maturity date						Mar. 31, 2021
Notice period for prepayment of tem loan						15 days
Debt Instrument, Fee Amount								$ 625,000
End-of-term fee				1,000,000		$ 1,000,000		1,000,000
EBITDA, less than						5,000,000
Lymphoseek sales revenue, less than						$ 11,000,000
Target revenue minimum								45,000,000
Cure right ratio						2.50%
Liquidity minimum								5,000,000
Debt unamortized discount, Net								2,200,000
Unamortized debt discount				2,100,000		$ 2,100,000
CRG Term Loan | Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Early payment percentage						5.00%
CRG Term Loan | Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Early payment percentage						1.00%
CRG Term Loan | Debt Instrument, Redemption, Period Three [Member]
Debt Instrument [Line Items]
Early payment percentage						0.00%
Oxford Finance, LLC
Debt Instrument [Line Items]
Debt face amount										$ 30,000,000
Debt instrument, interest rate										8.50%
Notes payable								26,900,000
End-of-term fee								2,400,000
Repayments of debt		$ 31,600,000
Early redemption fee								289,000
Loss on extinguishment of debt		$ (2,400,000)
Oxford Finance, LLC | Series KK warrants
Debt Instrument [Line Items]
Number of shares underlying warrant issued | shares										391,032
Exercise price of warrant issued, dollars per share | $ / shares										$ 1.918
Warrants expiration period			2021-03
Platinum Credit Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, increase in accrued interest						$ 462,000
Notes payable				8,200,000		$ 8,200,000
Debt instrument, maturity date						Sep. 30, 2021
Maximum borrowing capacity, amount				$ 50,000,000		$ 50,000,000		$ 35,000,000
Effective interest rate				14.125%		14.125%
Convertible threshold trading days | d						10
Share price trigger | $ / shares						$ 2.53
Proceeds from notes payable						$ 4,500,000
Conversion option fair value				$ 4,100,000		4,100,000
Change in fair value of financial instruments				1,600,000	$ 402,000	1,700,000	$ 104,000
Estimated fair value				12,300,000		12,300,000
Unused borrowing capacity				27,300,000		27,300,000
Unused additional borrowing capacity				$ 15,000,000		$ 15,000,000
Platinum Credit Facility [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, basis spread on variable rate						6.75%
Platinum Credit Facility [Member] | Interest Rate Pursuant to CGR Term Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, basis spread on variable rate						0.125%
Platinum Credit Facility [Member] | Minimum
Debt Instrument [Line Items]
Debt instrument, interest rate				10.00%		10.00%

Equity (Narrative) (Details)

Equity (Narrative) (Details)	9 Months Ended
	Sep. 30, 2015USD ($)shares
Class Of Stock [Line Items]
Stock issued during period value	$ 131,261
Common Stock
Class Of Stock [Line Items]
Shares of common stock issued | shares	72,476
Stock issued during period value	$ 72
Board of Directors | Common Stock
Class Of Stock [Line Items]
Shares of common stock issued | shares	72,476
Stock issued during period value	$ 131,000

Stock Warrants (Narrative) (Det

Stock Warrants (Narrative) (Details) - USD ($)	1 Months Ended			3 Months Ended	9 Months Ended
	Sep. 30, 2015	Aug. 31, 2015	Jul. 31, 2015	Sep. 30, 2015	Sep. 30, 2015	Mar. 11, 2015
Class of Warrant or Right [Line Items]
Extension of warrant expiration date					$ (149,615)
Preferred Stock, Shares Outstanding		0
Fair value of warrants issued or issuable recorded as a non-cash selling, general and administrative expense					$ 256,450
Warrants outstanding (shares)	16,600,000			16,600,000	16,600,000
Common Stock | Macrophage Therapeutics
Class of Warrant or Right [Line Items]
Exercise price of warrant issued, dollars per share	$ 2,000			$ 2,000	$ 2,000
Number of shares underlying warrant issued	300			300	300	300
Minimum
Class of Warrant or Right [Line Items]
Exercise price of warrant issued, dollars per share	$ 0.01			$ 0.01	$ 0.01
Warrant, Outstanding Term					0 years
Maximum
Class of Warrant or Right [Line Items]
Exercise price of warrant issued, dollars per share	3.04			3.04	$ 3.04
Warrant, Outstanding Term					20 years
Weighted Average
Class of Warrant or Right [Line Items]
Exercise price of warrant issued, dollars per share	0.25			$ 0.25	$ 0.25
Platinum Management New York L L C
Class of Warrant or Right [Line Items]
Exchanged Series B Preferred Stock for warrants to purchase common stock, shares		4,519
Convertible preferred stock, each shares issued upon conversion		3,270
Convertible preferred stock, shares issuable upon conversion		14,777,130
Platinum Management New York L L C | Minimum
Class of Warrant or Right [Line Items]
Common stock distribution or issuance effective price		$ 1.35
Series BB warrants
Class of Warrant or Right [Line Items]
Warrant, outstanding extended term			3 years
Warrant, outstanding extended term, month and year			2018-07
Extension of warrant expiration date				$ 149,615
Series LL Warrants | Platinum Management New York L L C
Class of Warrant or Right [Line Items]
Exercise price of warrant issued, dollars per share		$ 0.01
Number of common stock called by warrant are exercisable		14,777,130
Series MM warrants | Chardan Capital Markets, LLC
Class of Warrant or Right [Line Items]
Exercise price of warrant issued, dollars per share	$ 2.50			$ 2.50	$ 2.50
Number of warrants issued to purchase common stock				150,000
Common Stock Warrants Issuable				150,000
Fair value of warrants issued or issuable recorded as a non-cash selling, general and administrative expense				$ 256,000
Warrant, Outstanding Term	4 years

Reduction in Force (Narrative)

Reduction in Force (Narrative) (Details)	1 Months Ended	9 Months Ended
	Mar. 31, 2015employee	Sep. 30, 2015USD ($)
Restructuring and Related Activities [Abstract]
Restructuring costs		$ 1,300,000
Restructuring costs related to equity awards		$ 273,000
Staff Members [Member]
Restructuring and Related Activities [Abstract]
Number of employees terminated, staff | employee	7
Executives [Member]
Restructuring and Related Activities [Abstract]
Number of employees terminated, staff | employee	3

Reduction in Force - Summary of

Reduction in Force - Summary of Changes in Accrued Separation Costs (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Restructuring Reserve [Roll Forward]
Accrued separation costs, December 31, 2014	$ 449,351
Charges incurred with reduction in force	1,300,000
Accrued separation costs, September 30, 2015	39,404
Reduction in Force, May 2014
Restructuring Reserve [Roll Forward]
Payments related to reduction in force	(409,947)
Reduction in Force, March 2015
Restructuring Reserve [Roll Forward]
Payments related to reduction in force	(994,572)
Charges incurred with reduction in force	$ 994,572

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Liability for uncertain tax positions	$ 0	$ 0

Segments (Narrative) (Details)

Segments (Narrative) (Details)	9 Months Ended
	Sep. 30, 2015Segment
Segment Reporting [Abstract]
Number of reporting segments	2

Segments (Details)

Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	$ 2,952,522	$ 1,101,071	$ 6,751,492	$ 2,773,959
Lymphoseek license revenue	550,000	300,000	883,333	300,000
Grant and other revenue	476,755	848,999	1,320,816	1,002,605
Total revenue	3,979,277	2,250,070	8,955,641	4,076,564
Cost of goods sold, excluding depreciation and amortization	442,094		1,167,141
Research and development expenses, excluding depreciation and amortization	3,900,638		10,169,900
Selling, general and administrative expenses, excluding depreciation and amortization	3,827,393		13,137,061
Depreciation and amortization	132,229		431,368	360,702
Loss from operations	(4,323,077)	(5,362,486)	(15,949,829)	(23,157,087)
Other income (expense), excluding equity in the loss of R-NAV, LLC	(3,721,242)		(8,808,202)
Equity in the loss of R-NAV, LLC	(26,785)	(262,198)	(295,217)	(262,198)
Net loss	(8,071,104)	$ (6,898,896)	(25,053,248)	(28,861,683)
Total assets, net of depreciation and amortization	17,483,457		17,483,457		$ 11,830,308
Payments to Acquire Property, Plant, and Equipment	2,788		30,406	$ 1,111,418
Corporate
Segment Reporting Information [Line Items]
Selling, general and administrative expenses, excluding depreciation and amortization	2,721,844		8,381,910
Depreciation and amortization	115,216		223,870
Loss from operations	(2,837,060)		(8,605,780)
Other income (expense), excluding equity in the loss of R-NAV, LLC	(3,721,242)		(8,808,202)
Equity in the loss of R-NAV, LLC	(26,785)		(295,217)
Net loss	(6,585,087)		(17,709,199)
Payments to Acquire Property, Plant, and Equipment	2,788		4,914
United States
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	2,942,498		6,736,418
Total assets, net of depreciation and amortization	17,042,641		17,042,641
United States | Corporate
Segment Reporting Information [Line Items]
Total assets, net of depreciation and amortization	13,291,939		13,291,939
International
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	10,024		15,074
Total assets, net of depreciation and amortization	440,816		440,816
International | Corporate
Segment Reporting Information [Line Items]
Total assets, net of depreciation and amortization	467		467
Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Lymphoseek license revenue	550,000		883,333
Grant and other revenue	476,755		1,320,816
Total revenue	3,979,277		8,955,641
Cost of goods sold, excluding depreciation and amortization	442,094		1,167,141
Research and development expenses, excluding depreciation and amortization	3,603,501		9,610,012
Selling, general and administrative expenses, excluding depreciation and amortization	1,063,062		4,634,279
Depreciation and amortization	17,013		207,498
Loss from operations	(1,146,393)		(6,663,289)
Net loss	(1,146,393)		(6,663,289)
Payments to Acquire Property, Plant, and Equipment			25,492
Diagnostics | United States | Operating Segments
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	2,942,498		6,736,418
Total assets, net of depreciation and amortization	3,750,702		3,750,702
Diagnostics | International | Operating Segments
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	10,024		15,074
Total assets, net of depreciation and amortization	440,349		440,349
Therapeutics | Operating Segments
Segment Reporting Information [Line Items]
Research and development expenses, excluding depreciation and amortization	297,137		559,888
Selling, general and administrative expenses, excluding depreciation and amortization	42,487		120,872
Loss from operations	(339,624)		(680,760)
Net loss	$ (339,624)		$ (680,760)

Segments (Parenthetical) (Detai

Segments (Parenthetical) (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 132,229	$ 431,368	$ 360,702
Cost of Goods Sold
Segment Reporting Information [Line Items]
Depreciation and amortization	15,496	72,237
Research and Development
Segment Reporting Information [Line Items]
Depreciation and amortization	1,517	10,617
Selling, General and Administrative Expenses
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 115,216	$ 348,514

Supplemental Disclosure for S48

Supplemental Disclosure for Statements of Cash Flows (Details) - USD ($)	1 Months Ended	9 Months Ended
	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Supplemental Disclosure For Statements Of Cash Flows [Line Items]
Cash paid during the period for interest		$ 3,300,000	$ 2,100,000
End-of-term fee		1,000,000	$ 2,400,000
Derivative liabilities		63,000		$ 0
Deemed dividend on beneficial conversion feature of MT Preferred Stock		$ 46,000
Convertible Preferred Stock
Supplemental Disclosure For Statements Of Cash Flows [Line Items]
Deemed dividend on beneficial conversion feature of MT Preferred Stock	$ 46,000
Macrophage Therapeutics | Convertible Preferred Stock
Supplemental Disclosure For Statements Of Cash Flows [Line Items]
Deemed dividend on beneficial conversion feature of MT Preferred Stock	$ 46,000